20 June 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2023

16 June 2023 6 mins read

Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021

16 June 2023 4 mins read

Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance

14 June 2023 9 mins read

Correction: Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma

14 June 2023 9 mins read

Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma

13 June 2023 8 mins read

U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome

13 June 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2023

12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023

12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023

12 June 2023 11 mins read

Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023